| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Common Stock | Options Exercise | $0 | +44.9K | +6.19% | $0.00 | 770K | Aug 10, 2022 | Direct | F1 |
| transaction | SUPN | Common Stock | Sale | -$888K | -28.4K | -3.69% | $31.22 | 741K | Aug 10, 2022 | Direct | F1, F2 |
| holding | SUPN | Common Stock | 1.05M | Aug 10, 2022 | By the KBT Trust | ||||||
| holding | SUPN | Common Stock | 4K | Aug 10, 2022 | By son | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -44.9K | -100% | $0.00* | 0 | Aug 10, 2022 | Common Stock | 44.9K | $7.90 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.51, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| F3 | The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. |
| F4 | The option vested in four equal annual installments beginning on February 5, 2014. |